TY  - JOUR
T1  - BRca1 and brca2 mutations in ovarian cancer—reply
AU  - Zhang W, Yang D, Sood AK
Y1  - 2012/01/25
N1  - 10.1001/jama.2012.10
JO  - JAMA
SP  - 359
EP  - 361
VL  - 307
IS  - 4
N2  - 
In Reply:  Drs Buerkle and Tempfer asked whether differences in progression-free survival and primary chemotherapy response between BRCA1 - and BRCA2 -mutated cases could be the result of unbalanced distribution of disease stages and extent of cytoreduction. The distribution of cytoreduction outcomes between BRCA1 - and BRCA2 -mutated cases was similar (P = .94; Table 1 in the article). Although there was an apparent difference in the proportion of stage IV cases between BRCA1- and BRCA2- mutated cases, it was not significant (P = .28).

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.10
UR  - http://dx.doi.org/10.1001/jama.2012.10
ER  -